Coherence Neuro raises $10m for cancer treatment technology
Make us a preferred source
Make us a preferred source on Google
The news: Blackbird-backed healthcare startup Coherence Neuro has closed a $10 million seed round for its cancer management technology.
The context: The San Francisco-based company attracted new investors Possible Ventures, XEIA Venture Partners and Jumpspace Ventures, with follow-on investment from Blackbird Ventures, Topology Ventures, Artesian and Spacewalk VC. Artesian lead the round.
Coherence Neuro aims to change the way cancer is tracked and treated. Its flagship product SOMA is designed for people with glioblastoma, a type of cancer that starts as a growth of cells in the brain or spinal cord. The wearable device uses targeted electrical stimulation to disrupt tumour growth and collect data in real time.
What they said: "This is one of the most ambitious technical efforts we have seen at Blackbird, turning decades of neuroscience into a new way to fight cancer," said Blackbird general partner Michael Tolo in a LinkedIn post.
"But also an ambition that is quickly becoming reality, with first-in-human trials starting next year!"
"Bridging the gap between neuro and AI, we are generating the world’s largest, most comprehensive disease dataset," said Neuro co-founder Elise Jenkins on Linkedin.
"With our flagship device, SOMA-1, we will listen to the electrical cues that evolve as diseases progress and nudge them back towards a healthier state using electrical stimulation.
"Each device in a human becomes part of a learning system that gets more intelligent the more people use it. This round unlocks our first-in-human trial, edging us a step closer to delivering a closed-loop, bi-directional cancer treating system."
The source: LinkedIn
